ReviewFrontiers in oncology2022
Research Progress of Photothermal Nanomaterials in Multimodal Tumor Therapy.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Electromagnetic-Thermal Coupling Competition in Ag@TiONanomaterials (Basel, Switzerland) · 2026Article
- Strengthening D-A Push-Pull Interactions in BODIPY to Enhance Near-Infrared Absorption and Photothermal Conversion for Low-Intensity Photothermal Antitumor Therapy.Molecules (Basel, Switzerland) · 2026Article
- Nanomaterial-Based Photothermal Therapy for Inflammatory Diseases: Intervention Strategies, Synergistic Effects, and Future Challenges.International journal of nanomedicine · 2026Review
- Emerging photothermal agents combined with immunotherapy for cancer treatment.Discover oncology · 2025Review
- Optical parameter analysis and blood cells damage under 810 nm high-power IR laser irradiation before and post vitamin C and zinc supplementation.Lasers in medical science · 2025Article
- Insights into cellular and molecular mechanisms of graphene oxide nanoparticles in photothermal therapy for hepatocellular carcinoma.Scientific reports · 2025Article
- Recent advances in nano-molybdenum oxide for photothermal cancer therapy.Nanomedicine (London, England) · 2025Review
- Self-Assembled Nanoparticles: Overcoming Limitations of Conventional Nanomedicines for Enhanced Tumor Therapy.International journal of nanomedicine · 2025Review
- Exploring the therapeutic potential of lipid-based nanoparticles in the management of oral squamous cell carcinoma.Exploration of targeted anti-tumor therapy · 2024Review
- Fortification of Iron Oxide as Sustainable Nanoparticles: An Amalgamation with Magnetic/Photo Responsive Cancer Therapies.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aggressive growth of cancer cells brings extreme challenges to cancer therapy while triggering the exploration of the application of multimodal therapy methods. Multimodal tumor therapy based on photothermal nanomaterials is a new technology to realize tumor cell thermal ablation through near-infrared light irradiation with a specific wavelength, which has the advantages of high efficiency, less adverse reactions, and effective inhibition of tumor metastasis compared with traditional treatment methods such as surgical resection, chemotherapy, and radiotherapy. Photothermal nanomaterials have gained increasing interest due to their potential applications, remarkable properties, and advantages for tumor therapy. In this review, recent advances and the common applications of photothermal nanomaterials in multimodal tumor therapy are summarized, with a focus on the different types of photothermal nanomaterials and their application in multimodal tumor therapy. Moreover, the challenges and future applications have also been speculated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.